
The White House withdrew Dr. Heidi Overton’s nomination to lead the Food and Drug Administration late on 17 November 2026, the night before the Senate health committee was due to vote, leaving the agency under acting commissioner Kyle Diamantas. For drug and device sponsors, clinical researchers and university research offices, it means no Senate-confirmed FDA commissioner is likely to be in place for months.
What happened
The White House pulled the nomination on Tuesday evening after concluding that Overton lacked the Senate support to be confirmed, CNN reported, citing a White House official and two other people familiar with the matter. Axios reported the decision first. The Senate Health, Education, Labor and Pensions (HELP) Committee had scheduled a vote on Wednesday 18 November. According to the Associated Press, Overton would have needed the votes of all 12 Republicans on the committee, where Democrats hold 11 seats.
Trump announced the pick on 19 August, Medical Economics reported, to replace Marty Makary, who resigned as commissioner in May. Overton, a physician and White House domestic policy adviser, testified at a confirmation hearing on 24 September. Diamantas, the agency’s former deputy commissioner for food, has led the FDA on an acting basis since May, and CNN reported that the move is likely to leave the FDA without a permanent leader well into next year.
Key details
Several strands of opposition converged. CNN reported that conservative Sen. Josh Hawley and the anti-abortion movement were angered by the administration’s lack of urgency in restricting distribution of the abortion pill mifepristone, while Sens. Susan Collins and Lisa Murkowski raised concerns about Overton’s anti-abortion positions and her role in approving flavored vapes. The Associated Press reported that senators also questioned her independence on vaccines, and that committee chair Bill Cassidy had called her support for Trump’s plan to break up combination vaccines, including the measles, mumps and rubella shot, “almost disqualifying” before saying he was prepared to back her. CNN added that she was also criticised by allies of Health Secretary Robert F. Kennedy Jr. in the “Make America Healthy Again” movement.
| Date | Event | Source |
|---|---|---|
| May 2026 | Makary resigns; Kyle Diamantas becomes acting commissioner | Medical Economics, CIDRAP |
| 19 August 2026 | Trump announces Overton as nominee | Medical Economics |
| 24 September 2026 | Senate HELP confirmation hearing | Associated Press |
| 17 November 2026 | White House withdraws the nomination | CNN, CBS News |
| 18 November 2026 | Scheduled committee vote does not take place | BioPharma Dive |
Background and context
The Associated Press described the withdrawal as part of a string of health nominations pulled amid Republican resistance, including the first nominee for the Centers for Disease Control and Prevention and two surgeon general nominees. It reported that the FDA has lost about 20% of its employees to layoffs, buyouts, retirements or resignations since Trump took office. CBS News noted that the agency regulates products accounting for about 20% of US consumer spending and has had no Senate-confirmed leader since Makary was forced out in May. CASRAI has also covered the halted vote on the National Science Foundation director nominee in the same Senate committee, which Cassidy chairs, and the FDA’s global reliance disclosure program.
Reaction
Cassidy wrote on X that “the White House abandoned a viable confirmation path for Dr. Overton” and that “I believe she would have had the votes to pass out of committee and pass the full Senate.” He said that “pro-life Senators sought final assurances from the Administration regarding the Administration’s commitment to life issues” and that “the Administration withdrew Dr. Overton rather than make such commitments.” He added: “Unfortunately, with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats.” CIDRAP noted that Cassidy lost his Republican primary last spring and will leave the Senate, and the Associated Press that Republicans hand power to Senate Democrats in January. The MAHA Action group wrote that the next commissioner “must be aligned with the MAHA agenda”, CIDRAP reported.
BioPharma Dive reported that analysts do not expect disruption. RBC Capital Markets analyst Brian Abrahams wrote that the agency’s operations and drug approval processes are “likely to continue running reasonably smoothly”. The outlet noted that the agency has reversed many Makary-era decisions and installed more traditional leaders at two top drug offices.
What it means for researchers, universities and research offices
Sponsors and academic investigators who deal with the agency should plan for continuity under acting leadership rather than a change of direction. BioPharma Dive reported that Overton had advocated policies to speed the development of rare disease drugs and had pledged to convene more advisory panels and rely on career staff scientists; those commitments now lack a confirmed champion. For rare disease programmes, CASRAI’s guide to the FDA rare disease evidence principles describes the current evidence framework, and its explainer on the FDA drug approval process and the Prescription Drug User Fee Act entry show how review timelines are built.
Research offices supporting vaccine studies should watch the open vaccine questions that dominated the nomination, including the plan to separate combination vaccines, and the FDA’s mifepristone safety review, which BioPharma Dive said is expected to report by March 2027. Staffing is also a factor: about a fifth of FDA employees have left, as the Associated Press reported, while analysts quoted by BioPharma Dive expect routine operations to continue.
What happens next
It was not immediately clear when, or whether, the White House will name another nominee, the Associated Press reported. BioPharma Dive said Semafor had reported that Sen. Roger Marshall, a physician who lost his re-election campaign, could be the nominee. On the acting leadership, the Associated Press said federal rules limit acting officials to about seven months in the role, while BioPharma Dive reported that the 210-day limit on Diamantas’s service resets with the withdrawal. Cassidy said that confirming a permanent commissioner would fall to Senate Democrats after the January handover.
Sources
- CNN: White House drops Trump’s FDA pick amid senators’ opposition and ‘icy’ relationship with RFK Jr., 17 November 2026, checked 2026-11-18
- Los Angeles Times (Associated Press): White House pulls FDA nominee Heidi Overton after wavering support from Senate Republicans, 18 November 2026, checked 2026-11-18
- BioPharma Dive: White House pulls nomination for FDA nominee Overton, 18 November 2026, checked 2026-11-18
- CBS News: White House drops Heidi Overton’s nomination for FDA commissioner, checked 2026-11-18
- Medical Economics: White House withdraws Heidi Overton’s FDA nomination on eve of Senate committee vote, 17 November 2026, checked 2026-11-18
- CIDRAP: White House pulls Heidi Overton’s nomination for FDA chief, 18 November 2026, checked 2026-11-18







